Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280735
Status:
COMPLETED
Last Update Posted:
2017-07-11
First Post:
2006-01-19
Brief Title:
Ph II Adjuvant CarboplatinDocetaxel in Curatively Resected Stage I-IIIA NSCLC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
UNC Lineberger Comprehensive Cancer Center
Organization Data
Organization:
UNC Lineberger Comprehensive Cancer Center
Class:
OTHER
Study ID:
LCCC 0320
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Aventis Pharmaceuticals | INDUSTRY |